4:["$","div",null,{"className":"min-h-screen bg-white flex flex-col","children":[["$","div",null,{"className":"px-6 pt-6 pb-4 border-b border-gray-100","children":[["$","div",null,{"className":"flex items-center gap-1.5 text-xs text-gray-400 mb-4","children":[["$","a",null,{"href":"/","className":"hover:text-[#26a69a] transition-colors","children":"Market"}],["$","span",null,{"children":"›"}],["$","span",null,{"className":"text-gray-600","children":"Sarah Blagden"}]]}],["$","div",null,{"className":"text-[10px] text-gray-400 uppercase tracking-widest mb-1","children":"Company Profile"}],["$","h1",null,{"className":"text-2xl font-bold text-gray-900","children":"Sarah Blagden"}],null]}],["$","div",null,{"className":"flex-1 px-6 py-6","children":[["$","p",null,{"className":"text-sm text-gray-600 leading-relaxed mb-8","children":"Sarah Blagden is a Professor of Experimental Oncology at the University of Oxford. Her laboratory research is in investigating post-transcriptional mechanisms for ovarian cancer behavior. Her clinical research is in conducting early phase trials in novel cancer therapeutics for people with advanced malignancies."}],["$","div",null,{"className":"columns-1 md:columns-2 gap-10","children":[["$","div","0",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"Early life and education"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"Sarah Blagden was born in Aldershot, Hampshire in 1969. Her father was Brigadier Patrick Blagden, a renowned mine clearance expert. She was educated in Haslemere in Surrey, and later received a BSc in pharmacology in 1991 and a medical degree (MBBS) at Charing Cross and Westminster Medical School, University of London in 1994. In 2004, she received a PhD (as CRUK Clinical Fellow) in fruit fly genetics in the laboratory of Professor David Glover at Cambridge University. == Career =="}}]]}],["$","div","1",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"Career"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"After Blagden completed her medical training and subsequent specialist training in Medical Oncology at Addenbrooke's Hospital in Cambridge and the Royal Marsden Hospital, she went on to hold a Clinical Fellowship at the Institute of Cancer Research's Drug Development Unit. She serves on the Editorial Board of the British Journal of Cancer. In 2015, Blagden founded Prenostics a company dedicated to researching early cancer biomarkers. == Awards =="}}]]}],["$","div","2",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"Awards"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"• CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University. • CRUK clinical Fellow PhD in 2004 at Cambridge University. • Fellowship of Royal College Physicians in 2010. == References =="}}]]}]]}],"$Lf"]}],"$L10"]}]